Impact Factor
4.69
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
13.60
13,180 total citations
h5-index
118
h5 depth signal
Cited share
65.3%
673 of 1,030
Total citations
13,180
Citation footprint
Metric signal
8.44
External metric anchor
Self-citation
2.8%
364 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,473
China
1,240
United Kingdom
422
France
414
Italy
405
Citing Fields of Research
Liver Diseases
2,310
Hepatitis
2,293
Liver & Colon Cancer
798
Immunology
468
Cancer & Development
321
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
29,088
Articles tracked across the journal lifetime
Indexed publication set
1,030
673 cited publications
Last 12 months
322
26.8 publications/month
Open access share
15.8%
51 OA publications in the last year
Leading citing country
United States
2,473 citing publications
Leading citing field
Liver Diseases
2,310 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Jan. 1981-
v1n1,Jan. 1981-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hepatitis
Liver Diseases
Liver & Colon Cancer
Immunology
Broad Categories
Gastroenterology
Hepatitis
Liver Diseases
Liver & Colon Cancer
Transplantation
Substance Abuse
MeSH Descriptors
Liver Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/hep.0000000000001853
Open DOI
Present but not prescient: Cardiometabolic risk factors in alcohol-associated hepatitis
02
DOI 10.1097/hep.0000000000001820
Open DOI
Rethinking albumin after paracentesis: It’s not just about the volume
03
DOI 10.1097/hep.0000000000001852
Open DOI
Turning down the ammonia dial: Phase 2a evidence for YAQ007 in cirrhosis
04
05
DOI 10.1097/hep.0000000000001862
Open DOI
Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study
Background and Aims: Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction–associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresent...
06
DOI 10.1097/hep.0000000000001889
Open DOI
Upholding telomeres prevents hepatic stellate cell transdifferentiation and liver fibrogenesis
Background & Aims: Hepatic stellate cells (HSCs) are principal drivers of liver cirrhosis. Whether and how telomere dysfunction affects HSC function remain unclear. This study was undertaken to investigate the role of telomere maintenanc...
07
DOI 10.1097/hep.0000000000001888
Open DOI
Cinderella no more: Alpha-1 antitrypsin deficiency-associated liver disease steps into the ballroom
Was not provided for this article.
08
DOI 10.1097/hep.0000000000001887
Open DOI
Beyond the primary endpoint: Learning from “negative” AIH trials
Was not provided for this article.
09
DOI 10.1097/hep.0000000000001845
Open DOI
Erratum: Circular RNA sequencing identifies CircASAP1 as a key regulator in hepatocellular carcinoma metastasis
Was not provided for this article.
10
DOI 10.1097/hep.0000000000001819
Open DOI
Autoimmune hepatitis and primary biliary cholangitis are among a subset of autoimmune diseases defined by profound co-prevalence and genetic risk association with the IL12 pathway
Background and Aims: Distinct autoimmune diseases can share symptoms and autoantibodies, but the molecular pathways underlying this shared etiology remain poorly understood. We assessed genetic support for IL12 signaling across 27 diseas...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 11, no. 2 (FEB 1990)19910912 Notice published Printed on acid-free paper